Biotech alum William Roberts has moved to publicly traded Discovery Laboratories as VP of IR and corporate communications for the Warrington, Pa.-based company focused on respiratory disease care.
Discovery in November launched premature infant respiratory distress syndrome treatment Surfaxin in the U.S. Its Aerosurf treatment for RDS is in phase 2 clinical trials.
Roberts was VP-corporate comms. with oversight of IR at ViroPharma, which was acquired in January in a $4.2B deal by Shire. He was associate director of IR among other posts during 12 years at MedImmune.
Net loss for the fourth quarter 2013 was $11.7M.
Roberts reports to president/CEO John Cooper. In a statement, Cooper said Roberts will "coalesce our communications strategies so our customers and stakeholders fully understand the value and vision of Surfaxin and Aerosurtf.
Pharmaceutical PR vet Michael Parks advised the launch of Surfaxin through his Philadelphia-based Pitch360 firm. New York-based LifeSci Advisors was outside IR counsel.
Business leaders will face challenges in the upcoming year, some of which will come as a complete surprise, or beyond anyone's imagination.
Teneo has hired Philipp Grontzki, who is a 20-year veteran of corporate communications and financial journalism, as a managing director in its strategy and communications group.
Rowan Benecke, who co-founded Zeno Group and helmed Burson-Marsteller's tech practice, has joined McKinsey & Co as director of communications for North America.
BCW has named Golin's Matt Coldagelli EVP and leader of its corporate affairs practice in Chicago.
Abby Bailey, who headed corporate communications for Fedex in its Middle East, India and Africa region, has joined Teneo as managing director in Dubai.
Have a comment? Send it to 
No comments have been submitted for this story yet.